Point72 Asset Management
JNCE

Point72 Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Point72 Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-299,731
Closed -$701K – 1881
2022
Q3 		$701K Buy
299,731
+5,000
+2% +$17.7K ﹤0.01% 1119
2022
Q2 		$893K Buy
294,731
+9,900
+3% +$48.2K ﹤0.01% 1103
2022
Q1 		$1.93M Buy
284,831
+30,900
+12% +$220K 0.01% 880
2021
Q4 		$2.12M Buy
+253,931
New +$2.09M 0.01% 819
2020
Q1 		– Sell
-200,000
Closed -$1.75M – 1166
2019
Q4 		$1.75M Buy
+200,000
New +$1.08M 0.01% 638

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Point72 Asset Management's JNCE Position: Q4 2022 in Review

Point72 Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 299,731 shares — an estimated $701K sold.

Point72 Asset Management first reported a position in JNCE in Q4 2019 and held it in 5 quarters. The position peaked at $2.12M in Q4 2021. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • Point72 Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Point72 Asset Management sold 299,731 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $701K.
  • Point72 Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Point72 Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $2.12M in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Point72 Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.